BACKGROUND: Limited data exist about the role of second-line chemotherapy response assessed by positron emission tomography (PET) as a prognostic factor in patients with aggressive non-Hodgkin Lymphoma (NHL) who undergo autologous stem cell transplantation (ASCT). The objective of this analysis was to investigate the main determinants of prognosis in patients with aggressive B-cell NHL who undergo ASCT, focusing on the impact of pretransplantation PET, secondary age-adjusted International Prognostic Index (sAA-IPI) score, histology, and previous response to first-line chemotherapy. METHODS: Seventy-five patients with diffuse, large B-cell lymphoma or grade 3 follicular lymphoma who were treated at the author' institution with second-line chemotherapy (combined ifosfamide, etoposide, and epirubicin [IEV]) followed by ASCT between September 2002 and September 2006 were included. All patients were evaluated by PET after 1 to 3 courses of IEV chemotherapy before ASCT, and all patients received a conditioning regimen of combined carmustine, etoposide, cytosine arabinoside, and melphalan. The prognostic impact of pretransplantation PET, sAA-IPI score, histology, and previous response to first-line chemotherapy was evaluated by univariate and multivariate analyses. RESULTS: Seventy-two of 75 patients underwent ASCT. In a univariate analysis for progression-free survival (PFS) and overall survival (OS), a significant association was observed with pretransplantation PET (PFS, P< .00001; OS, P< .01) and previous first-line response (PFS, P= .02; OS, P= .04). In the multivariate framework, pretransplantation PET was identified as the only independent prognostic factor (PFS, P< .001; OS, P= .01). CONCLUSIONS: The current data indicated that pretransplantation PET is the main prognostic predictor in patients with aggressive B-cell NHL who are scheduled for ASCT.
BACKGROUND: Limited data exist about the role of second-line chemotherapy response assessed by positron emission tomography (PET) as a prognostic factor in patients with aggressive non-Hodgkin Lymphoma (NHL) who undergo autologous stem cell transplantation (ASCT). The objective of this analysis was to investigate the main determinants of prognosis in patients with aggressive B-cell NHL who undergo ASCT, focusing on the impact of pretransplantation PET, secondary age-adjusted International Prognostic Index (sAA-IPI) score, histology, and previous response to first-line chemotherapy. METHODS: Seventy-five patients with diffuse, large B-cell lymphoma or grade 3 follicular lymphoma who were treated at the author' institution with second-line chemotherapy (combined ifosfamide, etoposide, and epirubicin [IEV]) followed by ASCT between September 2002 and September 2006 were included. All patients were evaluated by PET after 1 to 3 courses of IEV chemotherapy before ASCT, and all patients received a conditioning regimen of combined carmustine, etoposide, cytosine arabinoside, and melphalan. The prognostic impact of pretransplantation PET, sAA-IPI score, histology, and previous response to first-line chemotherapy was evaluated by univariate and multivariate analyses. RESULTS: Seventy-two of 75 patients underwent ASCT. In a univariate analysis for progression-free survival (PFS) and overall survival (OS), a significant association was observed with pretransplantation PET (PFS, P< .00001; OS, P< .01) and previous first-line response (PFS, P= .02; OS, P= .04). In the multivariate framework, pretransplantation PET was identified as the only independent prognostic factor (PFS, P< .001; OS, P= .01). CONCLUSIONS: The current data indicated that pretransplantation PET is the main prognostic predictor in patients with aggressive B-cell NHL who are scheduled for ASCT.
Authors: Javier Briones; Silvana Novelli; José A García-Marco; José F Tomás; Teresa Bernal; Carlos Grande; Miguel A Canales; Antonio Torres; José M Moraleda; Carlos Panizo; Isidro Jarque; Francisca Palmero; Miguel Hernández; Eva González-Barca; Dulce López; Dolores Caballero Journal: Haematologica Date: 2013-10-25 Impact factor: 9.941
Authors: Philippe Armand; Arnon Nagler; Edie A Weller; Steven M Devine; David E Avigan; Yi-Bin Chen; Mark S Kaminski; H Kent Holland; Jane N Winter; James R Mason; Joseph W Fay; David A Rizzieri; Chitra M Hosing; Edward D Ball; Joseph P Uberti; Hillard M Lazarus; Markus Y Mapara; Stephanie A Gregory; John M Timmerman; David Andorsky; Reuven Or; Edmund K Waller; Rinat Rotem-Yehudar; Leo I Gordon Journal: J Clin Oncol Date: 2013-10-14 Impact factor: 44.544
Authors: Craig S Sauter; Matthew J Matasar; Jessica Meikle; Heiko Schoder; Gary A Ulaner; Jocelyn C Migliacci; Patrick Hilden; Sean M Devlin; Andrew D Zelenetz; Craig H Moskowitz Journal: Blood Date: 2015-03-10 Impact factor: 22.113
Authors: Ho-Young Yhim; Yael Eshet; Ur Metser; Chae-Hong Lim; Katherine Lajkosz; Keren Isaev; Matthew Cooper; Anca Prica; Vishal Kukreti; Sita Bhella; Noémie Lang; Kyung-Han Lee; Wei Xu; David Hodgson; Richard Tsang; Sang Eun Yoon; Seok Jin Kim; Won Seog Kim; Michael Crump; John Kuruvilla; Robert Kridel Journal: Blood Adv Date: 2020-11-24
Authors: Alex F Herrera; Matthew Mei; Lawrence Low; Haesook T Kim; Gabriel K Griffin; Joo Y Song; Reid W Merryman; Victoria Bedell; Christine Pak; Heather Sun; Tanya Paris; Tracey Stiller; Jennifer R Brown; Lihua E Budde; Wing C Chan; Robert Chen; Matthew S Davids; Arnold S Freedman; David C Fisher; Eric D Jacobsen; Caron A Jacobson; Ann S LaCasce; Joyce Murata-Collins; Auayporn P Nademanee; Joycelynne M Palmer; German A Pihan; Raju Pillai; Leslie Popplewell; Tanya Siddiqi; Aliyah R Sohani; Jasmine Zain; Steven T Rosen; Larry W Kwak; David M Weinstock; Stephen J Forman; Dennis D Weisenburger; Young Kim; Scott J Rodig; Amrita Krishnan; Philippe Armand Journal: J Clin Oncol Date: 2016-10-24 Impact factor: 44.544
Authors: Parastoo B Dahi; Roni Tamari; Sean M Devlin; Molly Maloy; Valkal Bhatt; Michael Scordo; Jenna Goldberg; Andrew D Zelenetz; Paul A Hamlin; Matthew J Matasar; Jocelyn Maragulia; Sergio A Giralt; Miguel-Angel Perales; Craig H Moskowitz; Craig S Sauter Journal: Biol Blood Marrow Transplant Date: 2014-08-28 Impact factor: 5.742